Western drugmakers have long struggled with India's populist attitude toward patents, but hoped there would be some light at the end of the tunnel with the latest spate of trade negotiations over generic drugs in the country. But Doctors Without Borders is none too pleased with the proposed trade changes and is urging Prime Minister Narendra Modi to adopt a similar attitude and stand up to international pressure.
Earlier this week, Chinese authorities released Peter Humphrey--a private eye linked to GlaxoSmithKline's 2013 bribery scandal--from local prison after a court reduced his sentence by about 7 months. And now, The Wall Street Journal reports that they've released his wife and partner Yu Yingzeng, too, cutting short her sentence by one month.
South Africa, facing a growing number of drug shortages, particularly of penicillin, is changing its inspection requirements in a move that will make it easier for drugmakers to switch suppliers of active pharmaceutical ingredients (APIs).
Last summer, Chinese prosecutors sentenced Peter Humphrey--a private eye linked to GlaxoSmithKline's 2013 bribery scandal--to 2.5 years in prison. But now, after serving about two years, he's been released.
Just weeks after AstraZeneca said it would build a new facility in Sweden where it intends to fill and package biologics, the U.K. drugmaker said it was doing something more traditional in Algeria. Through a joint venture there, it will build a $125 million small-molecule plant.
Quintiles has opened up a new, up-sized headquarters in China, toasting the country's growth as a global biopharma power and angling to play a bigger role in its continued evolution.
China has steeply raised the fees it requires to submit a medical device or a drug to the China Food and Drug Administration to more than $100,000. The move is expected to provide better funding for the regulator, which is struggling with a huge backlog of products awaiting approval.
German pharmaceutical giant Bayer said it expects to spend $3.4 million to expand its Indonesian production capacity for effervescents this year.
Quintiles, the world's largest CRO, is targeting the growing number of small and midsize biotech companies in Asia, porting its bespoke offering to the region in hopes of partnering with the continent's up-and-coming drug developers.
Medtronic CEO Omar Ishrak has long turned to emerging markets as a potential growth driver, and tapping into India's burgeoning population will play a key role in ramping up the company's business there, he said.